Elicio Therapeutics, Inc. Proceeds from Issuance of Warrants
Elicio Therapeutics, Inc. (ELTX) reported Proceeds from Issuance of Warrants of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-03-12
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for the quarter ending 2025-12-31 was $0.00.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for the quarter ending 2025-06-30 was $0.00.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for fiscal 2024 was $5.99M.
- Elicio Therapeutics, Inc. proceeds from issuance of warrants for fiscal 2023 was $0.00.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 9 month as first filed | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | -$16.90M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$16.90M derived: sum of 3 quarters · filed 2026-03-12 | $23.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | -$16.90M derived: sum of 2 quarters · filed 2026-03-12 | $23.00K derived: sum of 3 quarters · filed 2026-03-12 | $23.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | -$16.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $23.00K derived: sum of 2 quarters · filed 2026-03-12 | $23.00K derived: sum of 3 quarters · filed 2026-03-12 | $5.99M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $16.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $16.92M derived: sum of 2 quarters · filed 2025-11-13 | $22.88M 10-Q · filed 2025-11-13 | $17.47M 10-Q · filed 2024-11-13 | $22.88M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.96M 10-Q · filed 2025-08-07 | $5.96M derived: sum of 3 quarters · filed 2025-08-07 | $5.96M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $5.96M 10-Q · filed 2025-05-13 | $5.96M derived: sum of 2 quarters · filed 2025-05-13 | $5.96M derived: sum of 3 quarters · filed 2025-05-13 | $5.96M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |